HANSHOW
7.6.2024 10:31:31 CEST | Business Wire | Press release
Hanshow, a leader in Electronic Shelf Labels (ESLs) and digital retail solutions, and Leroy Merlin, a global DIY leader, have partnered to enhance customer and employee experiences by deploying ESLs across over 50,000 products integrated with the Leroy Merlin mobile app in France. Customers now enjoy seamless shopping with easy product geolocation and personalized recommendations in Leroy Merlin stores. After 18 months of R&D, they implemented a fully customized solution in all Leroy Merlin outlets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604438443/en/
Hanshow's ESL Solution at Leroy Merlin. (Graphic: Business Wire)
Enhanced Customer Support with Leroy Merlin's Mobile Application
This immersive experience is powered by the Leroy Merlin mobile application in conjunction with Hanshow's state-of-the-art ESL solutions. Leroy Merlin’s integration of Hanshow ESL into its app offers geolocation in-store to guide customers to products and aisles. This enhances the shopping experience and allows staff to provide more personalized advice and support.
The ESL solution also provides price consistency between online and offline channels, enriching user experience with various features such as customer reviews, enriched product descriptions, access the Home Index to assess a product's environmental and social impact, and the ability to flash labels directly from the application. These functions provide flexibility for consumers and store associates.
"We have successfully met the expectations of Leroy Merlin customers by developing a solution that enhances the in-store experience. By combining data and technological innovations, we have created a tailor-made tool that delivers a personalized experience for each customer," explains Pierre Fosseux, VP of Hanshow France.
Enhancing Retail Efficiency and Customer Experience
Whether it's stock management, restocking, or click-and-collect order preparation, the geolocation of products in the shop is a real time-saver for staff, who can devote themselves to focusing on higher-value tasks. "It now takes sales staff around 75 seconds to pick up a product, instead of 90 seconds previously, for orders placed online and picked up in the shop within a two-hour window chosen by the customer," says Olivier Personne, Merchandising Optimization Manager at Leroy Merlin. Eliminating price differences has positively improved customer satisfaction.
"The solution co-constructed with Hanshow enriches the customer experience across online and offline channels while simplifying in-store team tasks. Currently deployed in France, it is designed for larger-scale rollout in other Leroy Merlin locations," explains Hugues Hartung de la Roer, Concept & Merchandising Director at Leroy Merlin France.
Exemplifying both companies' commitment to enhancing customer satisfaction and driving innovation in the retail sector, the new solution not only simplifies the shopping process but also provides valuable data insights to improve store operations and customer engagement.
The collaboration won the Reta Awards 2024: Best In-store Solution for Leroy Merlin and Top Supplier for Hanshow, for transforming the retail environment with advanced technology.
About Leroy Merlin France
A pioneering company in the Adeo Group, Leroy Merlin is now the leading brand in France in all distribution channels for improving the home and the living environment. Specialising in the sale of products, projects and services, Leroy Merlin France has set itself the goal of building new ways of living with everyone, so that we can live better in the future, and puts customer satisfaction at the heart of its business.
About Hanshow
Hanshow is one of the global leaders in the development and manufacturing of electronic shelf labels and digital store solutions . The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores across more than 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604438443/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom